State Street
CCCC icon

State Street’s C4 Therapeutics CCCC Stock Holding History

State Street’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.9M Buy
2,115,621
+1,732,648
+452% +$5.93M ﹤0.01% 2743
2026
Q1 		$1.01M Buy
382,973
+40,200
+12% +$94.7K ﹤0.01% 3486
2025
Q4 		$655K Buy
342,773
+55,400
+19% +$131K ﹤0.01% 3616
2025
Q3 		$638K Hold
287,373
– – ﹤0.01% 3606
2025
Q2 		$411K Sell
287,373
-937,045
-77% -$1.36M ﹤0.01% 3660
2025
Q1 		$1.96M Buy
1,224,418
+1,400
+0.1% +$4.18K ﹤0.01% 3252
2024
Q4 		$4.4M Sell
1,223,018
-1,583,895
-56% -$7.88M ﹤0.01% 3027
2024
Q3 		$16M Sell
2,806,913
-188,035
-6% -$1.13M ﹤0.01% 2341
2024
Q2 		$13.8M Sell
2,994,948
-4,158,332
-58% -$24.8M ﹤0.01% 2367
2024
Q1 		$58.4M Buy
7,153,280
+6,997,907
+4,504% +$54.2M ﹤0.01% 1642
2023
Q4 		$878K Hold
155,373
– – ﹤0.01% 3507
2023
Q3 		$289K Hold
155,373
– – ﹤0.01% 3831
2023
Q2 		$427K Sell
155,373
-618,848
-80% -$1.99M ﹤0.01% 3731
2023
Q1 		$2.43M Sell
774,221
-1,673,376
-68% -$9.9M ﹤0.01% 3278
2022
Q4 		$14.4M Buy
2,447,597
+485,785
+25% +$4.03M ﹤0.01% 2465
2022
Q3 		$17.2M Buy
1,961,812
+1,245,369
+174% +$12.9M ﹤0.01% 2332
2022
Q2 		$5.4M Sell
716,443
-1,511,316
-68% -$13.3M ﹤0.01% 3064
2022
Q1 		$54M Buy
2,227,759
+638,006
+40% +$15.5M ﹤0.01% 1709
2021
Q4 		$51.2M Sell
1,589,753
-68,877
-4% -$2.72M ﹤0.01% 1791
2021
Q3 		$74.1M Buy
1,658,630
+288,008
+21% +$12.3M ﹤0.01% 1508
2021
Q2 		$51.9M Buy
1,370,622
+507,389
+59% +$18.2M ﹤0.01% 1817
2021
Q1 		$31.9M Buy
863,233
+698,102
+423% +$27.8M ﹤0.01% 2058
2020
Q4 		$5.47M Buy
+165,131
New +$4.79M ﹤0.01% 2917

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Bain Capital Life Sciences Investors
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street's CCCC Position: Q2 2026 in Review

State Street increased its C4 Therapeutics (CCCC) stake by 452% in Q2 2026, buying an estimated $5.93M and bringing the position to 2,115,621 shares worth $9.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2743.

State Street first reported a position in CCCC in Q4 2020 and has held it in 23 quarters since. The position peaked at $74.1M in Q3 2021. 147 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • State Street held 2,115,621 shares of C4 Therapeutics worth $9.9M as of Q2 2026.
  • State Street bought 1,732,648 C4 Therapeutics shares in Q2 2026, an estimated $5.93M.
  • C4 Therapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #2743 holding.
  • State Street first reported a position in C4 Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • State Street's C4 Therapeutics position peaked at $74.1M in Q3 2021.
  • 147 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.